Journal Home
Search for

Volume 19, Issue 10, Pages 1403-1408 (October 2008)


View previous. 6 of 32 View next.

Quantitative 3T MR Imaging of the Descending Thoracic Aorta: Patients with Familial Hypercholesterolemia Have an Increased Aortic Plaque Burden Despite Long-Term Lipid-lowering Therapy

Stephan A. Schmitz, MDaCorresponding Author Informationemail address, Declan P. O'Regan, PhDa, Julie Fitzpatricka, Clare Neuwirthbc, Elizabeth Potterbc, Isabella Tosibc, Joseph V. Hajnal, PhDa, Rossi P. Naoumova, MDbc

Received 4 November 2007; received in revised form 15 June 2008; accepted 30 June 2008. published online 11 August 2008.

Purpose

To compare the aortic plaque burden in patients with heterozygous familial hypercholesterolemia on long-term statin treatment with that of matched control subjects.

Materials and Methods

The authors studied 11 heterozygous, nonsmoking, nondiabetic, and nonhypertensive patients with familial hypercholesterolemia (mean age, 44 years ± 10) who had been receiving cholesterol-lowering management for a mean of 12 years ± 5, including 8.25 years ± 4.24 with the highest tolerable doses of a statin (or a statin plus ezetimibe), and 26 age- and sex-matched control subjects with 3T magnetic resonance (MR) imaging of the descending thoracic aorta by using an axial T2-weighted turbo spin-echo sequence.

Results

Quantitative analysis demonstrated that the aortic vessel wall area was significantly larger in patients with familial hypercholesterolemia than in control subjects (123 mm2 ± 23 vs 102 mm2 ± 18, respectively; P < .007), as was vessel wall thickness (1.63 mm ± 0.28 vs 1.37 mm ± 0.16, respectively; P < .001). No significant difference was found between mean values of routine serum lipid and lipoprotein parameters.

Conclusions

The results of this preliminary study show that patients with heterozygous familial hypercholesterolemia have a higher aortic atherosclerotic plaque burden than control subjects at quantitative MR imaging despite long-term lipid-lowering therapy. This information may help design future studies evaluating plaque burden and cardiovascular risk.

a Imaging Sciences Department, MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital Campus, Du Cane Rd, London, W12 0NN England

b Clinical Research Facility, MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital Campus, Du Cane Rd, London, W12 0NN England

c Lipid Clinic, Hammersmith Hospital, London, England

Corresponding Author InformationAddress correspondence to S.A.S.

 D.P.O. has received a PhD stipend from Berlex Healthcare, United Kingdom.

PII: S1051-0443(08)00637-4

doi:10.1016/j.jvir.2008.06.020


View previous. 6 of 32 View next.